L. Puig - Concepedia

Author

L. Puig

Also Known As

A Rodríguez Jornet, Carlos Ferrandiz, Jose María Mir‐Bonafé, L Español_Puig, L L Puig, L L. PUIG, L PUIG, L Puig, L Puig Sanz, L. L. Puig

Publications

29.2K

Citations

H-Index

219

Concepts

All Affiliations

Hospital de Sant Pau Universitat Autònoma de Barcelona Hospital Universitari Germans Trias i Pujol Hospital Universitario de La Princesa University of Verona

About

L. Puig is an author at Hospital de Sant Pau specializing in medicine, dermatology, and psoriatic arthritis.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	37	103	6.3K
2	Public Health	8	8	847
3	Health Sciences	4	4	83
4	Social Sciences	3	3	75
5	Engineering	2	2	37

L. Puig

291

Publications

19.7K

Citations

H-Index

Page 1

	Year	Citations
Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials Richard G. Langley, Boni E. Elewski, Mark Lebwohl, New England Journal of Medicine	2014	1.9K
Epidemiology of atopic dermatitis in adults: Results from an international survey S. Barbarot, S. Auziere, A. Gadkari, Allergy	2018	849
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis Mark Lebwohl, Bruce Strober, Alan Menter, New England Journal of Medicine	2015	790
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial Iain B. McInnes, Arthur Kavanaugh, Alice B. Gottlieb, The Lancet Rheumatoid DisorderRheumatologyAutoimmune DiseaseMedicineRheumatic Diseases	2013	789
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial Christopher T. Ritchlin, Proton Rahman, Arthur Kavanaugh, Annals of the Rheumatic Diseases	2014	654
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials Kenneth B. Gordon, Bruce Strober, Mark Lebwohl, The Lancet Autoimmune DiseaseMedicineClinical TrialsClinical DermatologyModerate-to-severe Plaque Psoriasis	2018	627
Patient perspectives in the management of psoriasis: Results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey Mark Lebwohl, H. Bachelez, Giampiero Girolomoni, Journal of the American Academy of Dermatology Rheumatoid DisorderRheumatologyDisease ManagementPopulation-based Multinational AssessmentPatient Perspectives	2014	505
Development and validation of the International Hidradenitis Suppurativa Severity Score System ( <scp>IHS</scp> 4), a novel dynamic scoring system to assess <scp>HS</scp> severity Christos C. Zouboulis, Thrasyvoulos Tzellos, Gregor B. E. Jemec, British Journal of Dermatology	2017	430
Development of a real-time PCR assay for Trypanosoma cruzi detection in blood samples María Pirón, Roser Fisa, Natàlia Casamitjana, Acta Tropica Blood SamplesReal-time Pcr AssayParasitic ProtozoaMedicineAfrican Trypanosomiasis	2007	396
Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double‐blind, phase <scp>III NAVIGATE</scp> trial Richard G. Langley, Tsen‐Fang Tsai, Susan Flavin, British Journal of Dermatology	2017	336

Page 1